Research Analysts’ Weekly Ratings Changes for Absci (ABSI)

Several analysts have recently updated their ratings and price targets for Absci (NASDAQ: ABSI):

• 10/20/2026 – Absci had its “buy” rating reaffirmed by HC Wainwright.
• 10/16/2026 – Absci had its price target raised by KeyCorp from $16.00 to $20.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Absci had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Absci had its price target raised by JPMorgan Chase & Co. from $14.00 to $15.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Absci had its “buy” rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
• 9/28/2026 – Absci had its “buy” rating reaffirmed by Guggenheim.
• 9/23/2026 – Absci had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
• 9/9/2026 – Absci is now covered by Lifesci Capital. They set an “outperform” rating on the stock.
• 9/8/2026 – Absci was given a new $15.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 9/8/2026 – Absci had its price target raised by BTIG Research from $13.00 to $16.00. They now have a “buy” rating on the stock.

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that uses generative artificial intelligence and advanced biotechnology to discover and develop new medicines. Its integrated drug creation platform combines computational design with laboratory-based validation to identify potential therapeutic candidates, with a focus on biologics such as antibodies and other protein-based medicines.

The company’s technology is designed to support the creation of novel drug candidates from the earliest stages of discovery through preclinical development.